Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
Cells. 2022 Dec 28;12(1):131. doi: 10.3390/cells12010131.
Alzheimer's disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.
阿尔茨海默病（AD），曾经被认为是一种罕见的疾病，现在是老年人中最常见的痴呆症形式。目前的药物（胆碱酯酶抑制剂和谷氨酸拮抗剂）是安全的，但对大多数患者的益处有限，只能提供症状缓解，而不能成功治愈疾病。在过去的几十年中，人们非常需要开发一种治疗方法，以消除 AD 的根本原因，从而减缓易患个体的疾病进展。这就是为什么作用于多个方面的 I 期、II 期和 III 期研究，如认知改善、症状减轻和增强 AD 的基础生物学，对于阻止疾病的发展是至关重要的。本文讨论了目前的治疗策略，总结了现有药物的临床特征和药理学特性，以及分子对接分析。
